Cargando…

Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study

PURPOSE: This study aimed to evaluate the efficacy and safety of predeposit autologous RBC apheresis (PARA) in patients undergoing multilevel spinal fusion surgery. METHODS: A total of 112 patients from January 2020 to June 2022 were divided into two groups according to PARA: the PARA group (n = 51)...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xiao-Ping, Que, Wen-Jun, Yu, Ze-Bo, Shen, Jie-Liang, Hu, Zhen-Ming, Yang, Xiao-Liang, Hao, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225601/
https://www.ncbi.nlm.nih.gov/pubmed/37256088
http://dx.doi.org/10.3389/fmed.2023.1149093
_version_ 1785050409871605760
author Xu, Xiao-Ping
Que, Wen-Jun
Yu, Ze-Bo
Shen, Jie-Liang
Hu, Zhen-Ming
Yang, Xiao-Liang
Hao, Jie
author_facet Xu, Xiao-Ping
Que, Wen-Jun
Yu, Ze-Bo
Shen, Jie-Liang
Hu, Zhen-Ming
Yang, Xiao-Liang
Hao, Jie
author_sort Xu, Xiao-Ping
collection PubMed
description PURPOSE: This study aimed to evaluate the efficacy and safety of predeposit autologous RBC apheresis (PARA) in patients undergoing multilevel spinal fusion surgery. METHODS: A total of 112 patients from January 2020 to June 2022 were divided into two groups according to PARA: the PARA group (n = 51) and the control group (n = 61). The baseline characteristics of the patients, outcomes, transfusion cost, hospitalization cost, length of stay, complications, and changes in hemoglobin and hematocrit levels between the two groups were compared. RESULTS: The baseline characteristics were similar in both groups. No significant differences were found in functional outcomes, including VAS score (p = 0.159), ODI score (p = 0.214), JOA score (p = 0.752), and SF-36 score (p = 0.188) between the PARA and control groups. The amount and rate of intraoperative and perioperative allogeneic RBC transfusion were significantly higher in the control group than in the PARA group (p < 0.001). The postoperative (9.04 ± 3.21 vs. 11.05 ± 3.84, p = 0.004) and total length of stay (15.78 ± 3.79 vs. 17.36 ± 4.08, p = 0.038) in the PARA group were significantly lower than those in the control group, respectively. Despite no difference in hospitalization cost (p = 0.737), the total blood transfusion cost in the PARA group was significantly lower, compared with the control group (p < 0.001). For safety evaluation, there were no significant differences in Hb and Hct levels between the two groups at admission, on postoperative day 1, and postoperative day 3, respectively (p > 0.05). Moreover, the number of postoperative infections in the PARA group was significantly lower than that in the control group (p = 0.038). CONCLUSION: PARA was a novel, safe, and highly efficient technique for mass autologous blood preparation in a quite short preparation time. This method could significantly reduce the amount of allogeneic blood transfusion and length of stay, which could provide a theoretical basis for following clinical practice about the technique.
format Online
Article
Text
id pubmed-10225601
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102256012023-05-30 Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study Xu, Xiao-Ping Que, Wen-Jun Yu, Ze-Bo Shen, Jie-Liang Hu, Zhen-Ming Yang, Xiao-Liang Hao, Jie Front Med (Lausanne) Medicine PURPOSE: This study aimed to evaluate the efficacy and safety of predeposit autologous RBC apheresis (PARA) in patients undergoing multilevel spinal fusion surgery. METHODS: A total of 112 patients from January 2020 to June 2022 were divided into two groups according to PARA: the PARA group (n = 51) and the control group (n = 61). The baseline characteristics of the patients, outcomes, transfusion cost, hospitalization cost, length of stay, complications, and changes in hemoglobin and hematocrit levels between the two groups were compared. RESULTS: The baseline characteristics were similar in both groups. No significant differences were found in functional outcomes, including VAS score (p = 0.159), ODI score (p = 0.214), JOA score (p = 0.752), and SF-36 score (p = 0.188) between the PARA and control groups. The amount and rate of intraoperative and perioperative allogeneic RBC transfusion were significantly higher in the control group than in the PARA group (p < 0.001). The postoperative (9.04 ± 3.21 vs. 11.05 ± 3.84, p = 0.004) and total length of stay (15.78 ± 3.79 vs. 17.36 ± 4.08, p = 0.038) in the PARA group were significantly lower than those in the control group, respectively. Despite no difference in hospitalization cost (p = 0.737), the total blood transfusion cost in the PARA group was significantly lower, compared with the control group (p < 0.001). For safety evaluation, there were no significant differences in Hb and Hct levels between the two groups at admission, on postoperative day 1, and postoperative day 3, respectively (p > 0.05). Moreover, the number of postoperative infections in the PARA group was significantly lower than that in the control group (p = 0.038). CONCLUSION: PARA was a novel, safe, and highly efficient technique for mass autologous blood preparation in a quite short preparation time. This method could significantly reduce the amount of allogeneic blood transfusion and length of stay, which could provide a theoretical basis for following clinical practice about the technique. Frontiers Media S.A. 2023-05-15 /pmc/articles/PMC10225601/ /pubmed/37256088 http://dx.doi.org/10.3389/fmed.2023.1149093 Text en Copyright © 2023 Xu, Que, Yu, Shen, Hu, Yang and Hao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Xu, Xiao-Ping
Que, Wen-Jun
Yu, Ze-Bo
Shen, Jie-Liang
Hu, Zhen-Ming
Yang, Xiao-Liang
Hao, Jie
Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study
title Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study
title_full Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study
title_fullStr Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study
title_full_unstemmed Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study
title_short Clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study
title_sort clinical application of a modified predeposit autologous red blood cell apheresis in multistage spinal fusion: a single-center retrospective study
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225601/
https://www.ncbi.nlm.nih.gov/pubmed/37256088
http://dx.doi.org/10.3389/fmed.2023.1149093
work_keys_str_mv AT xuxiaoping clinicalapplicationofamodifiedpredepositautologousredbloodcellapheresisinmultistagespinalfusionasinglecenterretrospectivestudy
AT quewenjun clinicalapplicationofamodifiedpredepositautologousredbloodcellapheresisinmultistagespinalfusionasinglecenterretrospectivestudy
AT yuzebo clinicalapplicationofamodifiedpredepositautologousredbloodcellapheresisinmultistagespinalfusionasinglecenterretrospectivestudy
AT shenjieliang clinicalapplicationofamodifiedpredepositautologousredbloodcellapheresisinmultistagespinalfusionasinglecenterretrospectivestudy
AT huzhenming clinicalapplicationofamodifiedpredepositautologousredbloodcellapheresisinmultistagespinalfusionasinglecenterretrospectivestudy
AT yangxiaoliang clinicalapplicationofamodifiedpredepositautologousredbloodcellapheresisinmultistagespinalfusionasinglecenterretrospectivestudy
AT haojie clinicalapplicationofamodifiedpredepositautologousredbloodcellapheresisinmultistagespinalfusionasinglecenterretrospectivestudy